Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate

Fullerton, N.E., Boyd, M., Mairs, R.J. , Keith, W.N. , Alderwish, O., Brown, M.M., Livingstone, A. and Kirk, D. (2004) Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate. Prostate Cancer and Prostatic Diseases, 7(4), pp. 355-363. (doi:10.1038/sj.pcan.4500760)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1038/sj.pcan.4500760

Abstract

A targeted radiotherapy/gene therapy approach for prostate cancer, using the radiopharmaceutical [<sup>131</sup>1]meta- iodobenzylguanidine ([<sup>131</sup>1]MIBG), would restrict the effects of radiotherapy to malignant cells, thereby increasing efficacy and decreasing morbidity of radiotherapy. Prostate cancer cells were transfected with a transgene encoding the noradrenaline transporter (NAT) under the control of tumour-specific telomerase promoters, enabling them to actively take up [<sup>131</sup>1]MIBG. This led to tumour-specific cell kill. This strategy has the advantage of generating a radiological bystander effect, leading to the destruction of neighbouring tumour cells that have escaped transfection. This targeted approach could be a promising tumour-specific treatment option for prostate cancer.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Keith, Professor Nicol and Mairs, Professor Robert and Boyd, Dr Marie
Authors: Fullerton, N.E., Boyd, M., Mairs, R.J., Keith, W.N., Alderwish, O., Brown, M.M., Livingstone, A., and Kirk, D.
Subjects:R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Q Science > QH Natural history > QH426 Genetics
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Prostate Cancer and Prostatic Diseases
ISSN:1365-7852

University Staff: Request a correction | Enlighten Editors: Update this record